NewYork-Presbyterian Hospital has launched NYPConnect, a cross-campus mobile communication tool that securely and efficiently connects NewYork-Presbyterian staff members and providers to streamline patient care. NYPConnect earned the hospital recognition on the 2015 InformationWeek Elite 100, marking NewYork-Presbyterian Hospital’s third time ranking on the list of top business technology innovators in the U.S.

Nearly 50 clinicians, working in eight operating rooms, successfully performed New York City's first four-way kidney transplant at NewYork-Presbyterian Hospital/Columbia University Medical Center. Four patients, who otherwise had no compatible donor, received lifesaving kidneys.

Nathan Klein is the first person in the world to receive gene therapy in the brain to reduce the devastating effects of this disease. This research represents a significant step towards refining effective gene therapies to treat not only Parkinson's, but other neurological disorders – and could someday offer new hope to others with this debilitating disease.

Recently, 88-year-old Nathaniel Grier participated in a groundbreaking clinical trial for a potential alternative to traditional mitral valve surgery. This noninvasive technique enabled him to be treated and released within 48 hours. The procedure could change the way heart patients are treated in the future.

New data presented this week at the 49th Annual Scientific Session of the American College of Cardiology suggest that current guidelines for treating lipids may need to be refined in generally healthy persons with average low-density lipoprotein cholesterol (LDL-C, the bad cholesterol) and below average high-density lipoprotein cholesterol (HDL-C, the good cholesterol) levels.

As the first doctor in the United States to use an advanced new treatment for varicose veins -- called endovenous laser -- Dr. Robert J. Min, of New York Weill Cornell Medical Center, has naturally attracted a certain amount of attention. So much attention that he thinks that his other main specialty, uterine fibroids, has been somewhat overlooked.

Despite the common belief that the massively dilated and dysfunctional hearts of patients with severe end-stage heart failure are irreversibly damaged, recent evidence has shown that the support of these hearts with left ventricular assist devices (LVADs) can lead to normalization of heart structure and improved strength of heart muscle.

Hao Wu, Assistant Professor of Biochemistry at Weill Medical College and Graduate School of Medical Sciences of Cornell University, has been named one of a select group of Pew Scholars in the Biomedical Sciences for the year 2000. The prestigious award, which is given to only 20 outstanding young scientists each year, provides $240,000 to support her research for the next four years.